PPARG and ASS1: Targets of Metabolic Alteration in Venetoclax / Decitabine Resistant Acute Myeloid Leukemia

被引：0
|
作者：
Yamatani, Kotoko [1 ]
Watanabe, Tatsuro [2 ]
Saito, Kaori [1 ]
Maiti, Abhishek [3 ]
Yamashita, Satoshi [4 ]
Khasawneh, Abdullah [1 ]
Paran, Faith Jessica [5 ]
Hayes, Kala [6 ]
Borthakur, Gautam [6 ]
Harman, Joe R. [7 ]
Kimura, Shinya [8 ]
DiNardo, Courtney D. [6 ]
Milne, Thomas A. [7 ]
Andreeff, Michael [9 ]
Tabe, Yoko [1 ,6 ]
Konopleva, Marina Y. [6 ,10 ,11 ]
机构：
[1] Juntendo Univ, Grad Sch Med, Dept Clin Lab Med, Tokyo, Japan
[2] Saga Univ, Dept Drug Discovery & Biomed Sci, Fac Med, Saga, Japan
[3] MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
[4] Maebashi Inst Technol, Life Engn Dept, Fac Engn, Gunma, Japan
[5] Juntendo Univ, Grad Sch Med, Dept Res Support Utilizing Bioresource Bank, Tokyo, Japan
[6] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
[7] Univ Oxford, MRC Weatherall Inst Mol Med, Radcliffe Dept Med, MRC Mol Haematol Unit, Oxford, England
[8] Saga Univ, Div Hematol Resp Med & Oncol, Dept Internal Med, Saga, Japan
[9] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Sect Mol Hematol & Therapy, Houston, TX USA
[10] Montefiore Med Ctr, Dept Oncol, Bronx, NY USA
[11] Albert Einstein Coll Med, Bronx, NY USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-178554
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Report of four acute myeloid leukemia patients with sustained complete remission with less frequent administration of decitabine and venetoclax
    Aribi, Ahmed
    Salhotra, Amandeep
    Ball, Brian
    Stein, Anthony
    Marcucci, Guido
    Pullarkat, Vinod
    LEUKEMIA & LYMPHOMA, 2023, 64 (04) : 897 - 899
  • [42] A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia
    Manda, Sudhir
    Anz III, Bertrand M.
    Benton, Christopher
    Broun, E. Randolph
    Yimer, Habte A.
    Renshaw, John S.
    Geils Jr, George
    Berdeja, Jesus
    Cruz, Jose
    Melear, Jason M.
    Fanning, Suzanne
    Fletcher, Luke
    Li, Yukun
    Duan, Yinghui
    Werner, Michael E.
    Potluri, Jalaja
    Pai, Madhavi V.
    Donnellan, William B.
    HEMATOLOGICAL ONCOLOGY, 2024, 42 (03)
  • [43] Efficacy and safety of venetoclax in combination with azacitidine or decitabine in an outpatient setting in patients with untreated acute myeloid leukemia.
    Manda, Sudhir
    Anz, Bertrand Marquess
    Benton, Christopher
    Broun, E. Randolph
    Yimer, Habte Aragaw
    Melear, Jason M.
    Cruz, Jose C.
    Fanning, Suzanne
    Sharman, Jeff Porter
    Kang, Kingston
    Svensson, Anders
    Pai, Madhavi
    Geils, George F.
    Renshaw, John Scott
    Donnellan, William Bruce
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [44] The impact of secondary-type mutations in newly diagnosed acute myeloid leukemia treated with venetoclax and decitabine or azacitidine
    Doyel, Michael
    Bouligny, Ian Michael
    Murray, Graeme
    Patel, Tilak
    Boron, Josh
    Tran, Valerie
    Gor, Juhi
    Hang, Yiwei
    Thuy Ho
    Zacholski, Kyle
    Venn, Chad Michael
    Alnimer, Yanal Mufeed
    Wages, Nolan
    Grant, Steven
    Maher, Keri Renee
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [45] Updated Safety and Efficacy of Venetoclax with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia
    DiNardo, Courtney D.
    Pollyea, Daniel A.
    Jonas, Brian A.
    Konopleva, Marina
    Pullarkat, Vinod
    Wei, Andrew
    Kantarjian, Hagop M.
    Pigneux, Arnaud
    Recher, Christian
    Seymour, John F.
    Dunbar, Martin
    Xu, Tu
    Mabry, Mack
    Potluri, Jalaja
    Pratz, Keith
    Letai, Anthony
    BLOOD, 2017, 130
  • [46] A real-world study of infectious complications of venetoclax combined with decitabine or azacitidine in adult acute myeloid leukemia
    Zhu, Li-xia
    Chen, Rong-rong
    Wang, Lu-lu
    Sun, Jia-nai
    Zhou, De
    Li, Li
    Qian, Jie-jing
    Zhang, Yi
    Tong, Hong-yan
    Yu, Wen-juan
    Meng, Hai-tao
    Mai, Wen-yuan
    Xie, Wan-zhuo
    Jin, Jie
    Ye, Xiu-jin
    Zhu, Hong-hu
    SUPPORTIVE CARE IN CANCER, 2022, 30 (08) : 7031 - 7038
  • [47] Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine
    Nishi, Rie
    Shigemi, Hiroko
    Negoro, Eiju
    Okura, Miyuki
    Hosono, Naoko
    Yamauchi, Takahiro
    BMC CANCER, 2020, 20 (01)
  • [48] ULKI Presents As a Therapeutic Target to Sensitize Resistant Acute Myeloid Leukemia Cells to Venetoclax
    Betz, Heather
    Jiang, Xiaoyan
    BLOOD, 2024, 144 : 2776 - 2776
  • [49] Homoharringtonine sensitized resistant acute myeloid leukemia cells to venetoclax-induced apoptosis
    Yin, Zhao
    Gao, Ya
    Bu, Xiaoyin
    Wang, Junhui
    Yao, Zurong
    Liu, Qifa
    Zhang, Yu
    Yu, Guopan
    Ping, Baohong
    LEUKEMIA & LYMPHOMA, 2024, 65 (14) : 2138 - 2150
  • [50] Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine
    Rie Nishi
    Hiroko Shigemi
    Eiju Negoro
    Miyuki Okura
    Naoko Hosono
    Takahiro Yamauchi
    BMC Cancer, 20
12345